Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Michela Guardascione"'
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss , Pp 441-451 (2021)
A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is the cause of coronavirus disease 2019 (COVID-19). It emerged in China in 2019 and has since spread worldwide. COVID-19 has a wide spectrum of clinical scenarios, ra
Externí odkaz:
https://doaj.org/article/6d458923a26c42e1adf1972078596c6a
Autor:
Chiara Dalle Fratte, Jerry Polesel, Sara Gagno, Bianca Posocco, Elena De Mattia, Rossana Roncato, Marco Orleni, Fabio Puglisi, Michela Guardascione, Angela Buonadonna, Giuseppe Toffoli, Erika Cecchin
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3303 (2023)
Adequate imatinib plasma levels are necessary to guarantee an efficacious and safe treatment in gastrointestinal stromal tumor (GIST) and chronic myeloid leukemia (CML) patients. Imatinib is a substrate of the drug transporters ATP-binding cassette s
Externí odkaz:
https://doaj.org/article/b0f21feaa41d42bd9e515e0834d90dc5
Autor:
Martina Zanchetta, Valentina Iacuzzi, Bianca Posocco, Giorgia Bortolin, Ariana Soledad Poetto, Marco Orleni, Giovanni Canil, Michela Guardascione, Luisa Foltran, Valentina Fanotto, Fabio Puglisi, Sara Gagno, Giuseppe Toffoli
Publikováno v:
PLoS ONE, Vol 16, Iss 10 (2021)
Lenvatinib (LENVA) is an oral antineoplastic drug used for the treatment of hepatocellular carcinoma and thyroid carcinoma. LENVA therapeutic drug monitoring (TDM) should be mandatory for a precision medicine to optimize the drug dosage. To this end,
Externí odkaz:
https://doaj.org/article/f9a48936ad72401cbcdf79e1c04c6527
Autor:
Chiara Dalle Fratte, Michela Guardascione, Elena De Mattia, Eugenio Borsatti, Roberta Boschetto, Angelo Farruggio, Vincenzo Canzonieri, Loredana Romanato, Rachele Borsatti, Sara Gagno, Elena Marangon, Maurizio Polano, Angela Buonadonna, Giuseppe Toffoli, Erika Cecchin
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The standard of care for the first-line treatment of advanced gastrointestinal stromal tumor (GIST) is represented by imatinib, which is given daily at a standard dosage until tumor progression. Resistance to imatinib commonly occurs through the clon
Externí odkaz:
https://doaj.org/article/caf5822064d54605ad380abb620ffbd7
Autor:
Bianca Posocco, Mauro Buzzo, Ariana Soledad Poetto, Marco Orleni, Sara Gagno, Martina Zanchetta, Valentina Iacuzzi, Michela Guardascione, Fabio Puglisi, Debora Basile, Giacomo Pelizzari, Elena Marangon, Giuseppe Toffoli
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228822 (2020)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be
Externí odkaz:
https://doaj.org/article/34569d5e09024b22b48029e2e574d355
Autor:
Elena De Mattia, Jerry Polesel, Rossana Roncato, Adrien Labriet, Alessia Bignucolo, Eva Dreussi, Loredana Romanato, Michela Guardascione, Angela Buonadonna, Mario D'Andrea, Eric Lévesque, Derek Jonker, Félix Couture, Chantal Guillemette, Erika Cecchin, Giuseppe Toffoli
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Nuclear receptors act as mediators of cancer-related inflammation and gene expression. They have a regulatory effect on genes encoding proteins related to drug adsorption, distribution, metabolism, and excretion. The aim of the present study was to h
Externí odkaz:
https://doaj.org/article/33bf59e066744d10896b27f28e166d32
Autor:
Anna Michelotti, Marco de Scordilli, Lorenza Palmero, Michela Guardascione, Mario Masala, Rossana Roncato, Luisa Foltran, Elena Ongaro, Fabio Puglisi
Publikováno v:
Cells, Vol 10, Iss 8, p 2034 (2021)
Hepatocellular carcinoma (HCC) is the seventh most common cancer worldwide and the second leading cause of cancer-related mortality. HCC typically arises within a cirrhotic liver, but in about 20% of cases occurs in absence of cirrhosis. Among non-ci
Externí odkaz:
https://doaj.org/article/9827d7de86b3467e845011b919ce5e01
Autor:
Valentina Iacuzzi, Bianca Posocco, Martina Zanchetta, Marcella Montico, Elena Marangon, Ariana Soledad Poetto, Mauro Buzzo, Sara Gagno, Angela Buonadonna, Michela Guardascione, Bruno Casetta, Giuseppe Toffoli
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0225225 (2019)
The introduction of imatinib, an oral tyrosine kinase inhibitor, as first-line standard therapy in patients with unresectable, metastatic, or recurrent gastro-intestinal stromal tumor (GIST), strongly improved their treatment outcomes. However, thera
Externí odkaz:
https://doaj.org/article/cb7a17ede8b04212b1ec2330fbbe6edd
Autor:
Michela Guardascione, Giuseppe Toffoli
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 17, p 6302 (2020)
In advanced-stage hepatocellular carcinoma (HCC), systemic treatment represents the standard therapy. Target therapy has marked a new era based on a greater knowledge of molecular disease signaling. Nonetheless, survival outcomes and long-term respon
Externí odkaz:
https://doaj.org/article/31d778288b3345fc9a7aea7fc77f3879
Autor:
Elena De Mattia, Eva Dreussi, Marcella Montico, Sara Gagno, Chiara Zanusso, Luca Quartuccio, Salvatore De Vita, Michela Guardascione, Angela Buonadonna, Mario D’Andrea, Nicoletta Pella, Adolfo Favaretto, Enrico Mini, Stefania Nobili, Loredana Romanato, Erika Cecchin, Giuseppe Toffoli
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
There are clinical challenges related to adjuvant treatment in colorectal cancer (CRC) and novel molecular markers are needed for better risk stratification of patients. Our aim was to integrate our previously reported clinical-genetic prognostic sco
Externí odkaz:
https://doaj.org/article/8c9cffdab72048d894753ab219fd8b5a